VEGFA and preeclampsia: In addition to use of sFLT1 as a clinical biomarker for predicting preeclampsia development, clinical and experimental studies outlined above have strongly suggested that targeting sFLT1 and the VEGF signaling pathway may be a viable strategy to prevent or treat preeclampsia.